
    
      A 3 week randomised crossover study to investigate the effect of repeat oral dosing of
      CNV2197944 75 mg tid versus placebo for on the pain experienced in post-herpetic neuralgia
      (PHN. Each 3 week treatment period is seperated by a 2 week washout period. The primary
      outcome measure is the change from baseline in the PI-NRS after three weeks of treatment.
      Secondary outcome measures include pain responder rates, clinical and patient global
      impressions of pain, and the Neuropathic Pain Symptom Inventory.
    
  